

Enriqueta Felip

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/6041998/enriqueta-felip-publications-by-year.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

245
papers

45,597
citations

72
h-index

213
g-index

265
ext. papers

57,947
ext. citations

8.3
avg, IF

6.97
L-index

#	Paper	IF	Citations
245	SEOM-GECP-GETTHI Clinical Guidelines for the treatment of patients with thymic epithelial tumours (2021).. <i>Clinical and Translational Oncology</i> , 2022 , 24, 635	3.6	0
244	Phase II study of afatinib plus pembrolizumab in patients with squamous cell carcinoma of the lung following progression during or after first-line chemotherapy (LUX-Lung-IO).. <i>Lung Cancer</i> , 2022 , 166, 107-113	5.9	0
243	ESMO expert consensus statements on the management of EGFR mutant Non-Small Cell Lung Cancer.. <i>Annals of Oncology</i> , 2022 ,	10.3	2
242	Effectiveness of PD-(L)1 Inhibitors Alone or in Combination With Platinum-Doublet Chemotherapy in First-Line (1L) Non-Squamous Non-Small Cell Lung Cancer (nsq-NSCLC) With PD-L1-High Expression Using Real-World Data.. <i>Annals of Oncology</i> , 2022 ,	10.3	6
241	First-in-human, open-label, phase 1/2 study of the monoclonal antibody programmed cell death protein-1 (PD-1) inhibitor cetrelimab (JNJ-63723283) in patients with advanced cancers.. <i>Cancer Chemotherapy and Pharmacology</i> , 2022 , 89, 499	3.5	1
240	Hepatic Rupture as the Initial Presentation of an -Mutated Lung Adenocarcinoma: A Case Report.. <i>Frontiers in Oncology</i> , 2022 , 12, 837630	5.3	
239	Phase Ib/II study of ceritinib in combination with ribociclib in patients with ALK-rearranged non-small cell lung cancer.. <i>Lung Cancer</i> , 2022 , 166, 170-177	5.9	0
238	Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer.. <i>New England Journal of Medicine</i> , 2022 ,	59.2	59
237	Genetic landscape of patients with ALK-rearranged non-small-cell lung cancer (NSCLC) and response to ceritinib in ASCEND-1 study. <i>Lung Cancer</i> , 2021 , 163, 7-13	5.9	0
236	Female leadership in oncology-has progress stalled? Data from the ESMO W4O authorship and monitoring studies.. <i>ESMO Open</i> , 2021 , 6, 100281	6	1
235	First-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone (four cycles) in advanced non-small-cell lung cancer: CheckMate 9LA 2-year update. <i>ESMO Open</i> , 2021 , 6, 100273	6	17
234	Treatment Outcomes and Safety of Mobocertinib in Platinum-Pretreated Patients With EGFR Exon 20 Insertion-Positive Metastatic Non-Small Cell Lung Cancer: A Phase 1/2 Open-label Nonrandomized Clinical Trial. <i>JAMA Oncology</i> , 2021 , e214761	13.4	28
233	Future care for long-term cancer survivors: towards a new model. <i>Clinical and Translational Oncology</i> , 2021 , 1	3.6	0
232	Five-Year Outcomes From the Randomized, Phase III Trials CheckMate 017 and 057: Nivolumab Versus Docetaxel in Previously Treated Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2021 , 39, 723-733	2.2	94
231	A CT-based Radiomics Signature Is Associated with Response to Immune Checkpoint Inhibitors in Advanced Solid Tumors. <i>Radiology</i> , 2021 , 299, 109-119	20.5	14
230	Gender influence on work satisfaction and leadership for medical oncologists: a survey of the Spanish Society of Medical Oncology (SEOM). <i>ESMO Open</i> , 2021 , 6, 100048	6	2
229	Intracranial and extracranial efficacy of lorlatinib in patients with ALK-positive non-small-cell lung cancer previously treated with second-generation ALK TKIs. <i>Annals of Oncology</i> , 2021 , 32, 620-630	10.3	14

228	Interrelations between Patients' Clinicopathological Characteristics and Their Association with Response to Immunotherapy in a Real-World Cohort of NSCLC Patients. <i>Cancers</i> , 2021 , 13,	6.6	2
227	Has COVID-19 had a greater impact on female than male oncologists? Results of the ESMO Women for Oncology (W4O) Survey. <i>ESMO Open</i> , 2021 , 6, 100131	6	5
226	Updated Overall Survival Analysis From IMpower110: Atezolizumab Versus Platinum-Based Chemotherapy in Treatment-Naive Programmed Death-Ligand 1-Selected NSCLC. <i>Journal of Thoracic Oncology</i> , 2021 , 16, 1872-1882	8.9	16
225	Pemetrexed plus platinum with or without pembrolizumab in patients with previously untreated metastatic nonsquamous NSCLC: protocol-specified final analysis from KEYNOTE-189. <i>Annals of Oncology</i> , 2021 , 32, 881-895	10.3	35
224	LungBEAM: A prospective multicenter study to monitor stage IV NSCLC patients with EGFR mutations using BEAMing technology. <i>Cancer Medicine</i> , 2021 , 10, 5878-5888	4.8	1
223	Real-world treatment outcomes with brigatinib in patients with pretreated ALK+ metastatic non-small cell lung cancer. <i>Lung Cancer</i> , 2021 , 157, 9-16	5.9	2
222	Progression-Free and Overall Survival for Concurrent Nivolumab With Standard Concurrent Chemoradiotherapy in Locally Advanced Stage IIIA-B NSCLC: Results From the European Thoracic Oncology Platform NICOLAS Phase II Trial (European Thoracic Oncology Platform 6-14). <i>Journal of Thoracic Oncology</i> , 2021 , 16, 278-288	8.9	22
221	Molecular profiling of long-term responders to immune checkpoint inhibitors in advanced non-small cell lung cancer. <i>Molecular Oncology</i> , 2021 , 15, 887-900	7.9	6
220	Biomarker Discovery and Outcomes for Comprehensive Cell-Free Circulating Tumor DNA Versus Standard-of-Care Tissue Testing in Advanced Non-Small-Cell Lung Cancer. <i>JCO Precision Oncology</i> , 2021 , 5, 93-102	3.6	5
219	First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial. <i>Lancet Oncology</i> , 2021 , 22, 198-211	21.7	244
218	Acute kidney injury as a risk factor for mortality in oncological patients receiving check-point inhibitors. <i>Nephrology Dialysis Transplantation</i> , 2021 ,	4.3	6
217	Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung: Final analysis of the randomised phase 3 LUX-Lung 8 trial. <i>EClinicalMedicine</i> , 2021 , 37, 100940	11.3	5
216	Clinical definition of acquired resistance to immunotherapy in patients with metastatic non-small-cell lung cancer. <i>Annals of Oncology</i> , 2021 , 32, 1597-1607	10.3	4
215	Trastuzumab Deruxtecan in -Mutant Non-Small-Cell Lung Cancer. <i>New England Journal of Medicine</i> , 2021 ,	59.2	57
214	Brigatinib Versus Crizotinib in ALK Inhibitor-Naive Advanced ALK-Positive NSCLC: Final Results of Phase 3 ALTA-1L Trial. <i>Journal of Thoracic Oncology</i> , 2021 , 16, 2091-2108	8.9	19
213	Phase I prognostic online (PIPO): A web tool to improve patient selection for oncology early phase clinical trials. <i>European Journal of Cancer</i> , 2021 , 155, 168-178	7.5	
212	Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIa non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial. <i>Lancet</i> , 2021 , 398, 1344-1357	14.9	84
211	Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT study): an open-label, phase 1b/2, multicentre, randomised trial. <i>Lancet Respiratory Medicine</i> , 2020 , 8, 1133-1143	35.1	66

210	Tepotinib in Non-Small-Cell Lung Cancer with Exon 14 Skipping Mutations. <i>New England Journal of Medicine</i> , 2020 , 383, 931-943	59.2	201
209	Multiple low dose therapy as an effective strategy to treat EGFR inhibitor-resistant NSCLC tumours. <i>Nature Communications</i> , 2020 , 11, 3157	17.4	30
208	Choice of second-line systemic therapy in stage IV small cell lung cancer (SCLC) - A decision-making analysis amongst European lung cancer experts. <i>Lung Cancer</i> , 2020 , 146, 6-11	5.9	5
207	Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2020 , 38, 1505-1517	2.2	298
206	Impact of lorlatinib on patient-reported outcomes in patients with advanced ALK-positive or ROS1-positive non-small cell lung cancer. <i>Lung Cancer</i> , 2020 , 144, 10-19	5.9	8
205	Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF- β and PD-L1, in Second-Line Treatment of Patients With NSCLC: Results From an Expansion Cohort of a Phase 1 Trial. <i>Journal of Thoracic Oncology</i> , 2020 , 15, 1210-1222	8.9	46
204	Patient-reported outcomes following pembrolizumab or placebo plus pemetrexed and platinum in patients with previously untreated, metastatic, non-squamous non-small-cell lung cancer (KEYNOTE-189): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. <i>Lancet Oncology</i> , 2020 , 21, 387-397	21.7	54
203	Brain Penetration of Lorlatinib: Cumulative Incidences of CNS and Non-CNS Progression with Lorlatinib in Patients with Previously Treated ALK-Positive Non-Small-Cell Lung Cancer. <i>Targeted Oncology</i> , 2020 , 15, 55-65	5	39
202	Safety and efficacy of nazartinib (EGF816) in adults with EGFR-mutant non-small-cell lung carcinoma: a multicentre, open-label, phase 1 study. <i>Lancet Respiratory Medicine</i> , 2020 , 8, 561-572	35.1	26
201	Treatment of brain metastases in small cell lung cancer: Decision-making amongst a multidisciplinary panel of European experts. <i>Radiotherapy and Oncology</i> , 2020 , 149, 84-88	5.3	5
200	The International Association for the Study of Lung Cancer Global Survey on Molecular Testing in Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2020 , 15, 1434-1448	8.9	42
199	Atezolizumab for First-Line Treatment of PD-L1-Selected Patients with NSCLC. <i>New England Journal of Medicine</i> , 2020 , 383, 1328-1339	59.2	317
198	Updated guidelines for predictive biomarker testing in advanced non-small-cell lung cancer: a National Consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology. <i>Clinical and Translational Oncology</i> , 2020 , 22, 989-1003	3.6	36
197	Ceritinib plus Nivolumab in Patients with Advanced ALK-Rearranged Non-Small Cell Lung Cancer: Results of an Open-Label, Multicenter, Phase 1B Study. <i>Journal of Thoracic Oncology</i> , 2020 , 15, 392-403	8.9	29
196	Analysis of mismatch repair (MMR) proteins expression in a series of malignant pleural mesothelioma (MPM) patients. <i>Clinical and Translational Oncology</i> , 2020 , 22, 1390-1398	3.6	11
195	Evolution and Clinical Impact of EGFR Mutations in Circulating Free DNA in the BELIEF Trial. <i>Journal of Thoracic Oncology</i> , 2020 , 15, 416-425	8.9	13
194	Capturing Hyperprogressive Disease with Immune-Checkpoint Inhibitors Using RECIST 1.1 Criteria. <i>Clinical Cancer Research</i> , 2020 , 26, 1846-1855	12.9	35
193	Final Overall Survival and Other Efficacy and Safety Results From ASCEND-3: Phase II Study of Ceritinib in ALKi-Naive Patients With ALK-Rearranged NSCLC. <i>Journal of Thoracic Oncology</i> , 2020 , 15, 609-617	8.9	15

192	First-Line Lorlatinib or Crizotinib in Advanced -Positive Lung Cancer. <i>New England Journal of Medicine</i> , 2020 , 383, 2018-2029	59.2	196
191	Assessment of the psychosocial and economic impact according to sex in non-small cell lung cancer patients: an exploratory longitudinal study. <i>BMC Psychology</i> , 2020 , 8, 123	2.8	
190	Brigatinib Versus Crizotinib in Advanced ALK Inhibitor-Naive ALK-Positive Non-Small Cell Lung Cancer: Second Interim Analysis of the Phase III ALTA-1L Trial. <i>Journal of Clinical Oncology</i> , 2020 , 38, 3592-3603 ¹⁰⁴	2.3	
189	Capmatinib in Exon 14-Mutated or -Amplified Non-Small-Cell Lung Cancer. <i>New England Journal of Medicine</i> , 2020 , 383, 944-957	59.2	214
188	Treatment options beyond immunotherapy in patients with wild-type lung adenocarcinoma: a Delphi consensus. <i>Clinical and Translational Oncology</i> , 2020 , 22, 759-771	3.6	10
187	An open-label phase IB study to evaluate GSK3052230 in combination with paclitaxel and carboplatin, or docetaxel, in FGFR1-amplified non-small cell lung cancer. <i>Lung Cancer</i> , 2019 , 136, 74-79	5.9	11
186	Assessment of a New ROS1 Immunohistochemistry Clone (SP384) for the Identification of ROS1 Rearrangements in Patients with Non-Small Cell Lung Carcinoma: the ROSING Study. <i>Journal of Thoracic Oncology</i> , 2019 , 14, 2120-2132	8.9	28
185	Prophylactic cranial irradiation in stage IV small cell lung cancer: Selection of patients amongst European IASLC and ESTRO experts. <i>Radiotherapy and Oncology</i> , 2019 , 133, 163-166	5.3	19
184	Clinical utility of plasma-based digital next-generation sequencing in oncogene-driven non-small-cell lung cancer patients with tyrosine kinase inhibitor resistance. <i>Lung Cancer</i> , 2019 , 134, 72-78	5.9	15
183	Five-Year Overall Survival for Patients With Advanced Non-Small-Cell Lung Cancer Treated With Pembrolizumab: Results From the Phase I KEYNOTE-001 Study. <i>Journal of Clinical Oncology</i> , 2019 , 37, 2518-2527	2.2	424
182	Safety and Efficacy of Crizotinib in Patients With Advanced or Metastatic ROS1-Rearranged Lung Cancer (EUCROSS): A European Phase II Clinical Trial. <i>Journal of Thoracic Oncology</i> , 2019 , 14, 1266-1276	8.9	42
181	Afatinib in NSCLC With HER2 Mutations: Results of the Prospective, Open-Label Phase II NICHE Trial of European Thoracic Oncology Platform (ETOP). <i>Journal of Thoracic Oncology</i> , 2019 , 14, 1086-1094	8.9	56
180	Health-Related Quality of Life in KEYNOTE-010: a Phase II/III Study of Pembrolizumab Versus Docetaxel in Patients With Previously Treated Advanced, Programmed Death Ligand 1-Expressing NSCLC. <i>Journal of Thoracic Oncology</i> , 2019 , 14, 793-801	8.9	28
179	Safety evaluation of nivolumab added concurrently to radiotherapy in a standard first line chemo-radiotherapy regimen in stage III non-small cell lung cancer-The ETOP NICOLAS trial. <i>Lung Cancer</i> , 2019 , 133, 83-87	5.9	65
178	Clinical Management of Adverse Events Associated with Lorlatinib. <i>Oncologist</i> , 2019 , 24, 1103-1110	5.7	44
177	Consolidative thoracic radiotherapy in stage IV small cell lung cancer: Selection of patients amongst European IASLC and ESTRO experts. <i>Radiotherapy and Oncology</i> , 2019 , 135, 74-77	5.3	9
176	Pembrolizumab in patients with advanced non-small-cell lung cancer (KEYNOTE-001): 3-year results from an open-label, phase 1 study. <i>Lancet Respiratory Medicine</i> , 2019 , 7, 347-357	35.1	88
175	Genomic Profiling Identifies Outcome-Relevant Mechanisms of Innate and Acquired Resistance to Third-Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy in Lung Cancer. <i>JCO Precision Oncology</i> , 2019 , 3,	3.6	9

174	Resistance Mutations and Efficacy of Lorlatinib in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2019 , 37, 1370-1379	2.2	154
173	Immunotherapy with checkpoint inhibitors in non-small cell lung cancer: insights from long-term survivors. <i>Cancer Immunology, Immunotherapy</i> , 2019 , 68, 341-352	7.4	54
172	Safety and efficacy of pembrolizumab monotherapy in elderly patients with PD-L1-positive advanced non-small-cell lung cancer: Pooled analysis from the KEYNOTE-010, KEYNOTE-024, and KEYNOTE-042 studies. <i>Lung Cancer</i> , 2019 , 135, 188-195	5.9	99
171	Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Oncology</i> , 2019 , 20, 1655-1669	21.7	215
170	KEYNOTE-189: Updated OS and progression after the next line of therapy (PFS2) with pembrolizumab (pembro) plus chemo with pemetrexed and platinum vs placebo plus chemo for metastatic nonsquamous NSCLC.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 9013-9013	2.2	36
169	Randomized Phase II Trial of Seribantumab in Combination with Erlotinib in Patients with EGFR Wild-Type Non-Small Cell Lung Cancer. <i>Oncologist</i> , 2019 , 24, 1095-1102	5.7	16
168	A phase Ib/II study of HER3-targeting lumretuzumab in combination with carboplatin and paclitaxel as first-line treatment in patients with advanced or metastatic squamous non-small cell lung cancer. <i>ESMO Open</i> , 2019 , 4, e000532	6	5
167	Epidermal growth factor receptor first generation tyrosine-kinase inhibitors. <i>Translational Lung Cancer Research</i> , 2019 , 8, S235-S246	4.4	6
166	5 protein-based signature for resectable lung squamous cell carcinoma improves the prognostic performance of the TNM staging. <i>Thorax</i> , 2019 , 74, 371-379	7.3	5
165	Afatinib With Pembrolizumab for Treatment of Patients With Locally Advanced/Metastatic Squamous Cell Carcinoma of the Lung: The LUX-Lung IO/KEYNOTE 497 Study Protocol. <i>Clinical Lung Cancer</i> , 2019 , 20, e407-e412	4.9	6
164	Randomised phase 2 study of pembrolizumab plus CC-486 versus pembrolizumab plus placebo in patients with previously treated advanced non-small cell lung cancer. <i>European Journal of Cancer</i> , 2019 , 108, 120-128	7.5	33
163	Use of archival versus newly collected tumor samples for assessing PD-L1 expression and overall survival: an updated analysis of KEYNOTE-010 trial. <i>Annals of Oncology</i> , 2019 , 30, 281-289	10.3	56
162	Lung cancer in Spanish women: The WORLD07 project. <i>European Journal of Cancer Care</i> , 2019 , 28, e12941.4	1.4	3
161	Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer. <i>New England Journal of Medicine</i> , 2018 , 378, 2078-2092	59.2	2820
160	Nivolumab versus docetaxel in previously treated advanced non-small-cell lung cancer (CheckMate 017 and CheckMate 057): 3-year update and outcomes in patients with liver metastases. <i>Annals of Oncology</i> , 2018 , 29, 959-965	10.3	267
159	Osimertinib and other third-generation EGFR TKI in EGFR-mutant NSCLC patients. <i>Annals of Oncology</i> , 2018 , 29, i20-i27	10.3	54
158	Second-Line Treatment Options in Non-Small-Cell Lung Cancer: Report From an International Experts Panel Meeting of the Italian Association of Thoracic Oncology. <i>Clinical Lung Cancer</i> , 2018 , 19, 301-314	4.9	6
157	Evaluation of NGS and RT-PCR Methods for ALK Rearrangement in European NSCLC Patients: Results from the European Thoracic Oncology Platform Lungscape Project. <i>Journal of Thoracic Oncology</i> , 2018 , 13, 413-425	8.9	48

156	Phase 2 Study of the HSP-90 Inhibitor AUY922 in Previously Treated and Molecularly Defined Patients with Advanced Non-Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2018 , 13, 576-584	8.9	45
155	Association of the Lung Immune Prognostic Index With Immune Checkpoint Inhibitor Outcomes in Patients With Advanced Non-Small Cell Lung Cancer. <i>JAMA Oncology</i> , 2018 , 4, 351-357	13.4	357
154	CNS response to osimertinib in patients with T790M-positive advanced NSCLC: pooled data from two phase II trials. <i>Annals of Oncology</i> , 2018 , 29, 687-693	10.3	132
153	Prevalence and clinical association of gene mutations through multiplex mutation testing in patients with NSCLC: results from the ETOP Lungscape Project. <i>Annals of Oncology</i> , 2018 , 29, 200-208	10.3	17
152	Symptom and Quality of Life Improvement in LUX-Lung 8, an Open-Label Phase III Study of Second-Line Afatinib Versus Erlotinib in Patients With Advanced Squamous Cell Carcinoma of the Lung After First-Line Platinum-Based Chemotherapy. <i>Clinical Lung Cancer</i> , 2018 , 19, 74-83.e11	4.9	23
151	Safety and clinical activity of atezolizumab monotherapy in metastatic non-small-cell lung cancer: final results from a phase I study. <i>European Journal of Cancer</i> , 2018 , 101, 201-209	7.5	36
150	Association of ERBB Mutations With Clinical Outcomes of Afatinib- or Erlotinib-Treated Patients With Lung Squamous Cell Carcinoma: Secondary Analysis of the LUX-Lung 8 Randomized Clinical Trial. <i>JAMA Oncology</i> , 2018 , 4, 1189-1197	13.4	39
149	Health-related quality of life (HRQoL) in the KEYNOTE-189 study of pembrolizumab (pembro) or placebo (pbo) + pemetrexed (pem) + platinum (plt) for metastatic NSCLC.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 9021-9021	2.2	11
148	Phase Ib/II Study of Capmatinib (INC280) Plus Gefitinib After Failure of Epidermal Growth Factor Receptor (EGFR) Inhibitor Therapy in Patients With EGFR-Mutated, MET Factor-Dysregulated Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2018 , 36, 3101-3109	2.2	146
147	Final Overall Survival Analysis From a Study Comparing First-Line Crizotinib Versus Chemotherapy in ALK-Mutation-Positive Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2018 , 36, 2251-2258	2.2	197
146	OA12.01 Phase II Data for the MET Inhibitor Tepotinib in Patients with Advanced NSCLC and MET Exon 14-Skipping Mutations. <i>Journal of Thoracic Oncology</i> , 2018 , 13, S347	8.9	10
145	Current Status and Future Perspectives on Neoadjuvant Therapy in Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2018 , 13, 1818-1831	8.9	73
144	Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study. <i>Lancet Oncology, The</i> , 2018 , 19, 1654-1667	21.7	361
143	Overcoming EGFR-mediated osimertinib resistance through unique binding characteristics of second-generation EGFR inhibitors. <i>Nature Communications</i> , 2018 , 9, 4655	17.4	69
142	Brigatinib versus Crizotinib in ALK-Positive Non-Small-Cell Lung Cancer. <i>New England Journal of Medicine</i> , 2018 , 379, 2027-2039	59.2	427
141	Osimertinib in Pretreated T790M-Positive Advanced Non-Small-Cell Lung Cancer: AURA Study Phase II Extension Component. <i>Journal of Clinical Oncology</i> , 2017 , 35, 1288-1296	2.2	363
140	Immune-checkpoint inhibition in first-line treatment of advanced non-small cell lung cancer patients: Current status and future approaches. <i>Lung Cancer</i> , 2017 , 106, 70-75	5.9	26
139	Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm, phase 2 trial. <i>Lancet Respiratory Medicine, the</i> , 2017 , 5, 435-444	35.1	133

138	Pembrolizumab as first-line therapy for patients with PD-L1-positive advanced non-small cell lung cancer: a phase 1 trial. <i>Annals of Oncology</i> , 2017 , 28, 874-881	10.3	144
137	Immune-Related Gene Expression Profiling After PD-1 Blockade in Non-Small Cell Lung Carcinoma, Head and Neck Squamous Cell Carcinoma, and Melanoma. <i>Cancer Research</i> , 2017 , 77, 3540-3550	10.1	213
136	First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer. <i>New England Journal of Medicine</i> , 2017 , 376, 2415-2426	59.2	1474
135	Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial. <i>Lancet Oncology, The</i> , 2017 , 18, 874-886	21.7	314
134	Evaluation of the VeriStrat serum protein test in patients with advanced squamous cell carcinoma of the lung treated with second-line afatinib or erlotinib in the phase III LUX-Lung 8 study. <i>Lung Cancer</i> , 2017 , 109, 101-108	5.9	24
133	Phase Ib Study of Lumretuzumab Plus Cetuximab or Erlotinib in Solid Tumor Patients and Evaluation of HER3 and Heregulin as Potential Biomarkers of Clinical Activity. <i>Clinical Cancer Research</i> , 2017 , 23, 5406-5415	12.9	24
132	The accelerated path of ceritinib: Translating pre-clinical development into clinical efficacy. <i>Cancer Treatment Reviews</i> , 2017 , 55, 181-189	14.4	9
131	OA03.02 Atezolizumab as 1L Therapy for Advanced NSCLC in PD-L1 Selected Patients: Updated ORR, PFS and OS Data from the BIRCH Study. <i>Journal of Thoracic Oncology</i> , 2017 , 12, S251-S252	8.9	12
130	OA03.05 Analysis of Early Survival in Patients with Advanced Non-Squamous NSCLC Treated with Nivolumab vs Docetaxel in CheckMate 057. <i>Journal of Thoracic Oncology</i> , 2017 , 12, S253	8.9	35
129	Lung Cancer in Never-Smoking Women: A Sub-Analysis of the Spanish Female-Specific Database WORLD07. <i>Cancer Investigation</i> , 2017 , 35, 358-365	2.1	5
128	Medical oncology future plan of the Spanish Society of Medical Oncology: challenges and future needs of the Spanish oncologists. <i>Clinical and Translational Oncology</i> , 2017 , 19, 508-518	3.6	10
127	Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial. <i>Lancet Oncology, The</i> , 2017 , 18, 1590-1599	21.7	367
126	Convergent Akt activation drives acquired EGFR inhibitor resistance in lung cancer. <i>Nature Communications</i> , 2017 , 8, 410	17.4	80
125	Phase II Trial of Atezolizumab As First-Line or Subsequent Therapy for Patients With Programmed Death-Ligand 1-Selected Advanced Non-Small-Cell Lung Cancer (BIRCH). <i>Journal of Clinical Oncology</i> , 2017 , 35, 2781-2789	2.2	248
124	Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057). <i>Journal of Clinical Oncology</i> , 2017 , 35, 3924-3933	2.2	495
123	A randomized, open-label, multicenter, phase 3 study to compare the efficacy and safety of eribulin to treatment of physician's choice in patients with advanced non-small cell lung cancer. <i>Annals of Oncology</i> , 2017 , 28, 2241-2247	10.3	9
122	Dual MET and ERBB inhibition overcomes intratumor plasticity in osimertinib-resistant-advanced non-small-cell lung cancer (NSCLC). <i>Annals of Oncology</i> , 2017 , 28, 2451-2457	10.3	43
121	Efficacy of tyrosine kinase inhibitors in EGFR-mutant lung cancer women in a real-world setting: the WORLD07 database. <i>Clinical and Translational Oncology</i> , 2017 , 19, 1537-1542	3.6	4

120	The Potential of Combined Immunotherapy and Antiangiogenesis for the Synergistic Treatment of Advanced NSCLC. <i>Journal of Thoracic Oncology</i> , 2017 , 12, 194-207	8.9	132
119	A consensus statement on the gender perspective in lung cancer. <i>Clinical and Translational Oncology</i> , 2017 , 19, 527-535	3.6	16
118	Ceritinib plus nivolumab (NIVO) in patients (pts) with anaplastic lymphoma kinase positive (ALK+) advanced non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2017 , 35, 2502-2502	2.2	21
117	Efficacy and safety of lorlatinib in patients (pts) with ALK+ non-small cell lung cancer (NSCLC) with one or more prior ALK tyrosine kinase inhibitor (TKI): A phase I/II study.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 9006-9006	2.2	15
116	KEYNOTE-001: 3-year overall survival for patients with advanced NSCLC treated with pembrolizumab.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 9011-9011	2.2	16
115	Factors associated with better overall survival (OS) in patients with previously treated, PD-L1 ⁺ expressing, advanced NSCLC: Multivariate analysis of KEYNOTE-010.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 9090-9090	2.2	10
114	Phase II Trial of Atezolizumab As First-Line or Subsequent Therapy for Patients With Programmed Death-Ligand 1 ⁺ Selected Advanced Non-Small-Cell Lung Cancer (BIRCH). <i>Journal of Clinical Oncology</i> , 2017 , 35, 2781-2789	2.2	1
113	Phase III Randomized Trial of Ipilimumab Plus Etoposide and Platinum Versus Placebo Plus Etoposide and Platinum in Extensive-Stage Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2016 , 34, 3740-3748	2.2	319
112	A randomized, double-blind, phase III study comparing two doses of erlotinib for second-line treatment of current smokers with advanced non-small-cell lung cancer (CurrentS). <i>Lung Cancer</i> , 2016 , 99, 94-101	5.9	10
111	Multicenter Phase II Study of Whole-Body and Intracranial Activity With Ceritinib in Patients With ALK-Rearranged Non-Small-Cell Lung Cancer Previously Treated With Chemotherapy and Crizotinib: Results From ASCEND-2. <i>Journal of Clinical Oncology</i> , 2016 , 34, 2866-73	2.2	238
110	Assessment of health-related quality of life (HRQoL) in KEYNOTE-010: A phase 2/3 study of pembrolizumab vs docetaxel in patients with previously treated advanced NSCLC. <i>Annals of Oncology</i> , 2016 , 27, vi422	10.3	5
109	Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. <i>Lancet, The</i> , 2016 , 387, 1540-1550	40	3964
108	Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial. <i>Annals of Oncology</i> , 2016 , 27, 417-233	10.3	101
107	Economic Analysis of First-Line Treatment with Erlotinib in an EGFR-Mutated Population with Advanced NSCLC. <i>Journal of Thoracic Oncology</i> , 2016 , 11, 801-7	8.9	16
106	Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial. <i>Lancet Oncology, The</i> , 2016 , 17, 452-463	21.7	318
105	The Evolving Role of Nivolumab in Non-Small-Cell Lung Cancer for Second-Line Treatment: A New Cornerstone for Our Treatment Algorithms. Results From an International Experts Panel Meeting of the Italian Association of Thoracic Oncology. <i>Clinical Lung Cancer</i> , 2016 , 17, 161-8	4.9	13
104	Osimertinib Western and Asian clinical pharmacokinetics in patients and healthy volunteers: implications for formulation, dose, and dosing frequency in pivotal clinical studies. <i>Cancer Chemotherapy and Pharmacology</i> , 2016 , 77, 767-76	3.5	88
103	TG4010 immunotherapy and first-line chemotherapy for advanced non-small-cell lung cancer (TIME): results from the phase 2b part of a randomised, double-blind, placebo-controlled, phase 2b/3 trial. <i>Lancet Oncology, The</i> , 2016 , 17, 212-223	21.7	110

102	Pembrolizumab vs docetaxel for previously treated advanced NSCLC with a PD-L1 tumor proportion score (TPS) 1%-49%: Results from KEYNOTE-010.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 9024-9024 ^{2,3}	2.2	23
101	Nivolumab (nivo) vs docetaxel (doc) in patients (pts) with advanced NSCLC: CheckMate 017/057 2-y update and exploratory cytokine profile analyses.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 9025-9025	2.2	23
100	Long-term OS for patients with advanced NSCLC enrolled in the KEYNOTE-001 study of pembrolizumab (pembro).. <i>Journal of Clinical Oncology</i> , 2016 , 34, 9026-9026	2.2	25
99	Updated results of a phase 1 study of EGF816, a third-generation, mutant-selective EGFR tyrosine kinase inhibitor (TKI), in advanced non-small cell lung cancer (NSCLC) harboring T790M.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 9044-9044	2.2	26
98	Lung Cancer in Women with a Family History of Cancer: The Spanish Female-specific Database WORLD07. <i>Anticancer Research</i> , 2016 , 36, 6647-6653	2.3	6
97	NSCLC, metastatic CheckMate 026: A phase 3 trial of nivolumab vs investigator's choice (IC) of platinum-based doublet chemotherapy (PT-DC) as first-line therapy for stage iv/recurrent programmed death ligand 1 (PD-L1) positive NSCLC. <i>Annals of Oncology</i> , 2016 , 27, vi577	10.3	59
96	A phase 2 study of seribantumab (MM-121) in combination with docetaxel or pemetrexed versus docetaxel or pemetrexed alone in patients with heregulin positive (HRG+), locally advanced or metastatic non-small cell lung cancer (NSCLC). <i>Annals of Oncology</i> , 2016 , 27, vi452	10.3	2
95	Intracranial Efficacy of Crizotinib Versus Chemotherapy in Patients With Advanced ALK-Positive Non-Small-Cell Lung Cancer: Results From PROFILE 1014. <i>Journal of Clinical Oncology</i> , 2016 , 34, 2858-65 ^{2,2}	2.2	171
94	Analysis of expression of PTEN/PI3K pathway and programmed cell death ligand 1 (PD-L1) in malignant pleural mesothelioma (MPM). <i>Lung Cancer</i> , 2016 , 96, 1-6	5.9	26
93	Systematic evaluation of pembrolizumab dosing in patients with advanced non-small-cell lung cancer. <i>Annals of Oncology</i> , 2016 , 27, 1291-8	10.3	91
92	Thoracic oncology HERMES: European curriculum recommendations for training in thoracic oncology. <i>Breathe</i> , 2016 , 12, 249-255	1.8	7
91	P2.39: Long-Term OS for Patients With Advanced NSCLC Enrolled in the KEYNOTE-001 Study of Pembrolizumab. <i>Journal of Thoracic Oncology</i> , 2016 , 11, S241-S242	8.9	17
90	Immunotherapy of non-small cell lung cancer: report from an international experts panel meeting of the Italian association of thoracic oncology. <i>Expert Opinion on Biological Therapy</i> , 2016 , 16, 1479-1489 ^{5,4}	5.4	10
89	Biomarker testing in advanced non-small-cell lung cancer: a National Consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology. <i>Clinical and Translational Oncology</i> , 2015 , 17, 103-12	3.6	21
88	Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial. <i>Lancet Oncology</i> , 2015 , 16, 897-907	21.7	314
87	Actualizaci3n de las recomendaciones para la determinaci3n de biomarcadores en el carcinoma de pulm3n avanzado de c3lula no peque1a. Consenso Nacional de la Sociedad Espa1a de Anatom3a Patol3gica y de la Sociedad Espa1a de Oncolog3a M3dica. <i>Revista Espanola De Patologia</i> , 2015 , 48, 80-89	1.2	1
86	AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer. <i>New England Journal of Medicine</i> , 2015 , 372, 1689-99	59.2	1447
85	Treatment of Elderly Patients With Non-Small-Cell Lung Cancer: Results of an International Expert Panel Meeting of the Italian Association of Thoracic Oncology. <i>Clinical Lung Cancer</i> , 2015 , 16, 325-33	4.9	55

84	Pembrolizumab for the treatment of non-small-cell lung cancer. <i>New England Journal of Medicine</i> , 2015 , 372, 2018-28	59.2	3943
83	Association of EGFR L858R Mutation in Circulating Free DNA With Survival in the EURTAC Trial. <i>JAMA Oncology</i> , 2015 , 1, 149-57	13.4	193
82	2nd ESMO Consensus Conference in Lung Cancer: locally advanced stage III non-small-cell lung cancer. <i>Annals of Oncology</i> , 2015 , 26, 1573-88	10.3	225
81	Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M. <i>Nature Medicine</i> , 2015 , 21, 560-2	50.5	1021
80	Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. <i>New England Journal of Medicine</i> , 2015 , 373, 1627-39	59.2	5964
79	A randomized phase II study of ganetespib, a heat shock protein 90 inhibitor, in combination with docetaxel in second-line therapy of advanced non-small cell lung cancer (GALAXY-1). <i>Annals of Oncology</i> , 2015 , 26, 1741-8	10.3	73
78	BIM and mTOR expression levels predict outcome to erlotinib in EGFR-mutant non-small-cell lung cancer. <i>Scientific Reports</i> , 2015 , 5, 17499	4.9	40
77	El cãncer de pulmã en mujeres. <i>Arbor</i> , 2015 , 191, a235	0.2	
76	Management of crizotinib therapy for ALK-rearranged non-small cell lung carcinoma: an expert consensus. <i>Lung Cancer</i> , 2015 , 87, 89-95	5.9	33
75	ASCEND-2: A single-arm, open-label, multicenter phase II study of ceritinib in adult patients (pts) with ALK-rearranged (ALK+) non-small cell lung cancer (NSCLC) previously treated with chemotherapy and crizotinib (CRZ).. <i>Journal of Clinical Oncology</i> , 2015 , 33, 8059-8059	2.2	39
74	ASCEND-3: A single-arm, open-label, multicenter phase II study of ceritinib in ALK+ naïve adult patients (pts) with ALK-rearranged (ALK+) non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2015 , 33, 8060-8060	2.2	47
73	Phase III, randomized trial (CheckMate 057) of nivolumab (NIVO) versus docetaxel (DOC) in advanced non-squamous cell (non-SQ) non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2015 , 33, LBA109-LBA109	2.2	59
72	Analysis of expression of programmed cell death 1 ligand 1 (PD-L1) in malignant pleural mesothelioma (MPM). <i>PLoS ONE</i> , 2015 , 10, e0121071	3.7	160
71	Ceritinib in ALK-rearranged non-small-cell lung cancer. <i>New England Journal of Medicine</i> , 2014 , 370, 1189-97	59.2	1119
70	2nd ESMO Consensus Conference on Lung Cancer: early-stage non-small-cell lung cancer consensus on diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2014 , 25, 1462-74	10.3	268
69	The impact of EGFR T790M mutations and BIM mRNA expression on outcome in patients with EGFR-mutant NSCLC treated with erlotinib or chemotherapy in the randomized phase III EURTAC trial. <i>Clinical Cancer Research</i> , 2014 , 20, 2001-10	12.9	182
68	Efficacy and Safety of Ceritinib in Patients (Pts) with Advanced Anaplastic Lymphoma Kinase (Alk)-Rearranged (Alk+) Non-Small Cell Lung Cancer (Nsclc): an Update of Ascend-1. <i>Annals of Oncology</i> , 2014 , 25, iv456	10.3	21
67	Overall and Intracranial (Ic) Efficacy Results and Time to Symptom Deterioration in Profile 1014: 1St-Line Crizotinib Vs Pemetrexed - Platinum Chemotherapy (Ppc) in Patients (Pts) with Advanced Alk-Positive Non-Squamous Non-Small Cell Lung Cancer (Nsclc). <i>Annals of Oncology</i> , 2014 , 25, iv427	10.3	8

66	2nd ESMO Consensus Conference on Lung Cancer: non-small-cell lung cancer first-line/second and further lines of treatment in advanced disease. <i>Annals of Oncology</i> , 2014 , 25, 1475-84	10.3	174
65	First-line crizotinib versus chemotherapy in ALK-positive lung cancer. <i>New England Journal of Medicine</i> , 2014 , 371, 2167-77	59.2	2116
64	Second ESMO consensus conference on lung cancer: pathology and molecular biomarkers for non-small-cell lung cancer. <i>Annals of Oncology</i> , 2014 , 25, 1681-1690	10.3	208
63	Lungscape: resected non-small-cell lung cancer outcome by clinical and pathological parameters. <i>Journal of Thoracic Oncology</i> , 2014 , 9, 1675-84	8.9	19
62	Unusual forms of subacute invasive pulmonary aspergillosis in patients with solid tumors. <i>Journal of Infection</i> , 2014 , 69, 387-95	18.9	14
61	Lung cancer in women: an overview with special focus on Spanish women. <i>Clinical and Translational Oncology</i> , 2014 , 16, 517-28	3.6	17
60	First-line crizotinib versus pemetrexed+isplatin or pemetrexed+carboplatin in patients (pts) with advanced ALK-positive non-squamous non-small cell lung cancer (NSCLC): results of a phase III study (PROFILE 1014). <i>Journal of Clinical Oncology</i> , 2014 , 32, 8002-8002	2.2	30
59	Ceritinib in advanced anaplastic lymphoma kinase (ALK)-rearranged (ALK+) non-small cell lung cancer (NSCLC): Results of the ASCEND-1 trial.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 8003-8003	2.2	18
58	A randomized phase 2 trial of MM-121, a fully human monoclonal antibody targeting ErbB3, in combination with erlotinib in EGFR wild-type NSCLC patients.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 8051-8051	2.2	20
57	Evaluation of Ceritinib-Treated Patients (Pts) with Anaplastic Lymphoma Kinase Rearranged (Alk+) Non-Small Cell Lung Cancer (Nsclc) and Brain Metastases in the Ascend-1 Study. <i>Annals of Oncology</i> , 2014 , 25, iv455	10.3	14
56	SEOM clinical guidelines for the treatment of non-small cell lung cancer (NSCLC) 2013. <i>Clinical and Translational Oncology</i> , 2013 , 15, 977-84	3.6	17
55	Strategies for improving outcomes in NSCLC: a look to the future. <i>Lung Cancer</i> , 2013 , 82, 375-82	5.9	26
54	An open-label, multicenter, randomized, phase II study of pazopanib in combination with pemetrexed in first-line treatment of patients with advanced-stage non-small-cell lung cancer. <i>Journal of Thoracic Oncology</i> , 2013 , 8, 1529-37	8.9	31
53	Thoracic Oncology HERMES: a European syllabus towards a harmonised education and training of Thoracic Oncology specialists. <i>Breathe</i> , 2013 , 9, 381-392	1.8	3
52	Lung cancer that harbors an HER2 mutation: epidemiologic characteristics and therapeutic perspectives. <i>Journal of Clinical Oncology</i> , 2013 , 31, 1997-2003	2.2	453
51	Small-cell lung cancer (SCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2013 , 24 Suppl 6, vi99-105	10.3	390
50	Clinical response to a lapatinib-based therapy for a Li-Fraumeni syndrome patient with a novel HER2V659E mutation. <i>Cancer Discovery</i> , 2013 , 3, 1238-44	24.4	38
49	Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2013 , 24 Suppl 6, vi89-98	10.3	376

48	Fluorescence in situ hybridization and immunohistochemistry as diagnostic methods for ALK positive non-small cell lung cancer patients. <i>PLoS ONE</i> , 2013 , 8, e52261	3-7	58
47	HER2 driven non-small cell lung cancer (NSCLC): potential therapeutic approaches. <i>Translational Lung Cancer Research</i> , 2013 , 2, 122-7	4-4	37
46	Neoadjuvant chemotherapy in early-stage non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2013 , 2, 398-402	4-4	6
45	Adjuvant Chemotherapy: Feasibility in the Elderly and Patient Selection 2013 , 165-172		
44	Is There a Role for Neoadjuvant Chemotherapy in Older Patients? 2013 , 141-150		
43	Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. <i>Lancet Oncology</i> , 2012 , 13, 239-46	21.7	3985
42	Recomendaciones para la determinaci3n de biomarcadores en el carcinoma de pulm3n no microc3nico avanzado. Consenso nacional de la Sociedad Espa3ola de Anatom3a Patol3gica y de la Sociedad Espa3ola de Oncolog3a M3dica. <i>Revista Espanola De Patologia</i> , 2012 , 45, 14-28	1.2	6
41	Exploratory analysis of activation of PTEN-PI3K pathway and downstream proteins in malignant pleural mesothelioma (MPM). <i>Lung Cancer</i> , 2012 , 77, 192-8	5-9	53
40	Drug development to overcome resistance to EGFR inhibitors in lung and colorectal cancer. <i>Molecular Oncology</i> , 2012 , 6, 15-26	7-9	62
39	Guidelines for biomarker testing in advanced non-small-cell lung cancer. A national consensus of the Spanish Society of Medical Oncology (SEOM) and the Spanish Society of Pathology (SEAP). <i>Clinical and Translational Oncology</i> , 2012 , 14, 338-49	3-6	29
38	Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2012 , 23 Suppl 7, vii56-64	10-3	342
37	Safety and efficacy of first-line bevacizumab plus chemotherapy in elderly patients with advanced or recurrent nonsquamous non-small cell lung cancer: safety of avastin in lung trial (MO19390). <i>Journal of Thoracic Oncology</i> , 2012 , 7, 203-11	8-9	55
36	Never-smoking women with lung cancer from the Spanish WORLD07 database.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 1531-1531	2.2	1
35	Population survey to assess the knowledge of smoking habit and its consequences on women (w) in Spain.. <i>Journal of Clinical Oncology</i> , 2012 , 30, e12000-e12000	2.2	1
34	Menstrual status and lung cancer in female patients from the Spanish WORLD07 database.. <i>Journal of Clinical Oncology</i> , 2012 , 30, e12012-e12012	2.2	3
33	Adjuvant and neoadjuvant therapy of non-small cell lung cancer 2012 , 93-103		
32	Tissue sampling in lung cancer: a review in light of the MERIT experience. <i>Lung Cancer</i> , 2011 , 74, 1-6	5-9	32
31	Adjuvant therapy in non-small cell lung cancer: future treatment prospects and paradigms. <i>Clinical Lung Cancer</i> , 2011 , 12, 261-71	4-9	26

30	1st ESMO Consensus Conference in lung cancer; Lugano 2010: small-cell lung cancer. <i>Annals of Oncology</i> , 2011 , 22, 1973-1980	10.3	42
29	Metastatic non-small-cell lung cancer: consensus on pathology and molecular tests, first-line, second-line, and third-line therapy: 1st ESMO Consensus Conference in Lung Cancer; Lugano 2010. <i>Annals of Oncology</i> , 2011 , 22, 1507-1519	10.3	98
28	Erlotinib versus chemotherapy (CT) in advanced non-small cell lung cancer (NSCLC) patients (p) with epidermal growth factor receptor (EGFR) mutations: Interim results of the European Erlotinib Versus Chemotherapy (EURTAC) phase III randomized trial.. <i>Journal of Clinical Oncology</i> , 2011 , 29, 7503-7503	2.2	63
27	Small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2010 , 21 Suppl 5, v120-5	10.3	71
26	Preoperative chemotherapy plus surgery versus surgery plus adjuvant chemotherapy versus surgery alone in early-stage non-small-cell lung cancer. <i>Journal of Clinical Oncology</i> , 2010 , 28, 3138-45	2.2	228
25	A multicentre phase II gene expression profiling study of putative relationships between tumour biomarkers and clinical response with erlotinib in non-small-cell lung cancer. <i>Annals of Oncology</i> , 2010 , 21, 217-222	10.3	34
24	How to integrate current knowledge in selecting patients for first line in NSCLC?. <i>Annals of Oncology</i> , 2010 , 21 Suppl 7, vii230-3	10.3	5
23	Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2010 , 21 Suppl 5, v116-9	10.3	236
22	Early stage and locally advanced (non-metastatic) non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2010 , 21 Suppl 5, v103-15	10.3	369
21	Phase II proof-of-concept study of pazopanib monotherapy in treatment-naive patients with stage I/II resectable non-small-cell lung cancer. <i>Journal of Clinical Oncology</i> , 2010 , 28, 3131-7	2.2	120
20	Sunitinib in combination with gemcitabine plus cisplatin for advanced non-small cell lung cancer: a phase I dose-escalation study. <i>Lung Cancer</i> , 2010 , 70, 180-7	5.9	36
19	SEOM clinical guidelines for the treatment of non-small-cell lung cancer: an updated edition. <i>Clinical and Translational Oncology</i> , 2010 , 12, 735-41	3.6	11
18	A phase I safety and pharmacokinetic (PK) study of PI3K/TORC1/TORC2 inhibitor XL765 (SAR245409) in combination with erlotinib (E) in patients (pts) with advanced solid tumors.. <i>Journal of Clinical Oncology</i> , 2010 , 28, 3015-3015	2.2	8
17	Non-small-cell lung cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2009 , 20 Suppl 4, 68-70	10.3	107
16	SEOM guidelines for the management of non-small-cell lung cancer (NSCLC). <i>Clinical and Translational Oncology</i> , 2009 , 11, 284-9	3.6	12
15	Clinical surrogate markers of survival in advanced non-small cell lung cancer (NSCLC) patients treated with second-third line erlotinib. <i>Lung Cancer</i> , 2009 , 66, 257-61	5.9	16
14	Tumor regression and pharmacodynamic (PD) biomarker validation in non-small cell lung cancer (NSCLC) patients treated with the ErbB/VEGFR inhibitor BMS-690514. <i>Journal of Clinical Oncology</i> , 2009 , 27, 8098-8098	2.2	14
13	Symptom and quality of life results of an international randomised phase III study of adjuvant vaccination with Bec2/BCG in responding patients with limited disease small-cell lung cancer. <i>European Journal of Cancer</i> , 2008 , 44, 2178-84	7.5	32

12	Non-small-cell lung cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2008 , 19 Suppl 2, ii39-40	10.3	55
11	A phase II pharmacodynamic study of erlotinib in patients with advanced non-small cell lung cancer previously treated with platinum-based chemotherapy. <i>Clinical Cancer Research</i> , 2008 , 14, 3867-74	12.9	70
10	A phase II study of first-line erlotinib in patients (pts) with stage IIIB/IV non-small-cell lung cancer (NSCLC) including dose escalation to toxicity in current and former smokers (C/FS). <i>Journal of Clinical Oncology</i> , 2008 , 26, 8111-8111	2.2	3
9	Adjuvant chemotherapy in non-small cell lung cancer (NSCLC). <i>Annals of Oncology</i> , 2007 , 18 Suppl 9, ix143-6	10.3	3
8	Customizing cisplatin based on quantitative excision repair cross-complementing 1 mRNA expression: a phase III trial in non-small-cell lung cancer. <i>Journal of Clinical Oncology</i> , 2007 , 25, 2747-54	2.2	391
7	The expanding role of systemic treatment in non-small cell lung cancer neo-adjuvant therapy. <i>Annals of Oncology</i> , 2006 , 17 Suppl 10, x108-12	10.3	2
6	Phase III study of adjuvant vaccination with Bec2/bacille Calmette-Guerin in responding patients with limited-disease small-cell lung cancer (European Organisation for Research and Treatment of Cancer 08971-08971B; Silva Study). <i>Journal of Clinical Oncology</i> , 2005 , 23, 6854-64	2.2	179
5	BRCA1 mRNA expression levels as an indicator of chemoresistance in lung cancer. <i>Human Molecular Genetics</i> , 2004 , 13, 2443-9	5.6	258
4	Sequential dose-dense paclitaxel followed by topotecan in untreated extensive-stage small-cell lung cancer: a Spanish Lung Cancer Group phase II study. <i>Annals of Oncology</i> , 2003 , 14, 1549-54	10.3	7
3	Preoperative high-dose cisplatin versus moderate-dose cisplatin combined with ifosfamide and mitomycin in stage IIIA (N2) non small-cell lung cancer: results of a randomized multicenter trial. <i>Clinical Lung Cancer</i> , 2000 , 1, 287-93	4.9	8
2	Orbital metastases from transitional-cell cancer of the urinary bladder. <i>Urologia Internationalis</i> , 1991 , 46, 82-4	1.9	14
1	Multiple Low Dose (MLD) therapy: an effective strategy to treat EGFR inhibitor-resistant NSCLC tumours		1